Filter
97
Text search:
Lopinavir/Ritonavir
Featured
Recommendations
24
New Publications
28
Language
Document type
No document type
47
Guidelines
32
Fact sheets
8
Studies & Reports
6
Manuals
2
Training Material
1
Infographics
1
Countries / Regions
Ethiopia
3
India
3
Germany
3
Malawi
3
Russia
3
Burkina Faso
2
Nigeria
2
Ghana
2
Uganda
2
Nepal
2
Tanzania
2
Namibia
2
Madagascar
2
East and Southern Africa
2
West and Central Africa
2
Middle East and North Africa
2
Paraguay
2
France
2
Spain
2
Sierra Leone
1
Senegal
1
Mali
1
Côte d’Ivoire / Ivory Coast
1
Cameroon
1
Niger
1
Togo
1
Haiti
1
Zambia
1
Turkey
1
Kenya
1
Thailand
1
Rwanda
1
South Africa
1
Mozambique
1
Benin
1
Central African Republic
1
Peru
1
Burundi
1
Ecuador
1
Angola
1
Myanmar / Burma
1
Latin America and the Carribbean
1
Luxembourg
1
Venezuela
1
Djibouti
1
Congo-Brazzaville
1
Canada
1
Global
1
Belgium
1
Authors & Publishers
Publication Years
Category
Countries
49
Clinical Guidelines
9
Pharmacy & Technologies
3
Women & Child Health
2
Key Resources
1
Toolboxes
COVID-19
28
HIV
20
Pharmacy
12
TB
3
Ebola
1
Mental Health
1
Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended
This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up
...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE
...
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of Tuberculosis Elimination.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
CDC Afrique est préoccupé par les informations inexactes distribués par les médias traditionnels et sociaux en ce qui concerne la prévention et le traitement des maladies nouvelles coronavirus (Covid-19).
Sur la base d’un examen des preuves et de l’évaluation d’experts, le CDC Afrique r
...
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Nirmatrelvir-ritonavir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
The Africa Centres for Disease Control and Prevention (Africa CDC) is concerned about inaccurate information being distributed through traditional and social media regarding prevention and treatment of novel coronavirus disease (COVID-19).
As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I
...
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
NEMLIST | Sixth Edition | February 2016
La Agencia Española de Medicamentos y Producto Sanitarios (AEMPS) está monitorizando de manera continua con los expertos de las agencias europeas, la EMA y el resto de agencias mundiales todos los datos relativos al uso de medicamentos para tratar la COVID-19. Se trata de
...
El presente documento técnico tiene la finalidad de guiar el manejode cuidados intensivosde los pacientes conCOVID-19 con undoble objetivo: lograr el mejor tratamiento del paciente que contribuya a subuena evolución clínica; ygarantizar los niveles adecuados de prevención y control de la
...
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
